Scientists have discovered how aspirin could prevent some types of cancer from spreading, describing it as “the moment of urea”.
The new research depends on the current evidence that indicates aspirin that supports a boost in the immune system to help capture deadly cancer cells.
Clinical experiments in cancer Patients, who are studying how aspirin can stop the return of the disease, but experts warn against taking aspirin routinely without speaking to the doctor.
The new research indicates that the aspirin path becomes a treatment for cancer, as well as the development of the most effective medications to prevent the spread of cancer.
The researchers examined 810 genes in mice and found 15 affecting the spread of cancer.
The study found that mice that lack a gene that produces a specific protein, called ARHGEF1, is less likely to spread cancer to the lungs and liver.
Scientists have found that ARHGEF1 inhibits a type of immune cell called T -cell, which is important for identifying the prevalent cancer cells (spreading to other parts of the body).
Discover unexpectedly that ARHGEF1 is running when the T cells are exposed to a specific coagulation factor, a protein that prevents excessive bleeding.
The clotting factor, called Thromboxane A2 (TXA2), is made by blood platelets in the blood – it is already known that aspirin cuts its production.
By reducing TXA2 production, aspirin can prevent some types of cancer from spreading.
In the mice that were given aspirin, the frequency of the metasta – the spread of cancer – compared to those that are not exposed to the drug, and the research, which was published in the journal Nature Journal and funded by the Medical Research Council and the Wellcome Trust.
Read more from Sky News:
Tattoos may be associated with the levels of risk of cancer – study
Cancer death rates “60 % higher” in disadvantaged areas
Dr. Ji Yang, from the team that led the study at the University of Cambridge, described the discovery about TXA2 as “the moment of Urika”.
“It was a completely unexpected discovery that sent us a completely different path to investigate what we expected,” said Dr. Yang.
“Aspirin, or other drugs that can target this path, have the ability to be less expensive than antibodies based, and therefore can be accessed worldwide.
Researchers are now working with Professor Ruth Langley at College University London, who leads a study on whether aspirin can stop or delay early stage cancers of the return.
Professor Langley said: “This is an important discovery. We will enable us to explain the results of continuous clinical trials and probably work to benefit from aspirin after diagnosing cancer,” said Professor Langley.
However, she warned: “In a small percentage of people, aspirin can cause serious side effects, including bleeding or stomach ulcers.
“Therefore, it is important to understand which people with cancer are likely to benefit, and they always speak to your doctor before starting aspirin.”